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The biomolecular mechanisms that mediate signal transduc:ion by type 11 (7) interferon (IFN) are poorly understood. IF'N-?. is a potent growth 
inhibitory cytokine also endow,'d with antiviral, immuDomodulatory, and differentiating activiti~ on various cell targets, including neural cell~. 
! FN-7 induced a rapid and transient activation of phosphollpase A: in LAN-5, a human neuroblastoma cell line. A consequence of phospholipase 
A, activation was the release of arachidonic acid and the generation of lysoptlospholipids tYom membrane phospholip;ds. Treatment of pre-labeled 
LAN-5 cells with a receptor-saturating concentration f IFN-~, led to a time-dependent release of [~H]arachidonic a id into the culture media nd 
generation of [UP]lysophosphatidylcholine. Pretreatment of cultures with the phospholipase A, inhibitor, bromophenacyl bromide, markedly 
inhibited both [SH]arachidonic a id release and lysophosphatidylcholine production i duced by IFN-y treatment. Pretrcatment of LAN-5 cells with 
nordihydroguaiaretic ac d, a lipoxygenase inhibitor, or with indomethaein, a cyclooxygenase inhibitor, amplifi~ the release of [3H]arachidonic a id 
and production of lysophosphatidyleholin~ induced by non-saturating concentrations of IFN-?.. In parallel, and with the same time-dependent 
effect, a significant decrease in phosphatidylcholine labeling was observed in IFN-?.-trcatcd cells, farther indicating that a potential signal 
transduction mechanism of IFN.?. is the hydrolysis of membrane phosphatidylcholine by phospholipase A,. 
Interferon-?'; Phospholipase A:; lndometbaein; Nordihydroguaiarctie acid (NDGA); Neuroblastoma 
1. INTRODUCTION 
1FN-7', a lymphokine produced by activated T lym- 
phocytes and NK cells, exerts a variety of biologic ef- 
fects, including antiviral, immunomodulatory, and anti- 
proliferative activities [1,2]. Moreover, IFN-7 interacts 
with cells other than those of the immune system, such 
as those of the nervous system, and may have a role in 
the interaction between the nervous and immune sys- 
tems [3], and exhibits differentiation-promoting effects 
on neuronal cells [4]. 1FN-~' exerts its biological func- 
tions via a cell-surface receptor, recently shown to be an 
ubiquitous protein occurring in different molecular 
forms on haman cells [5]. Recent studies suggest hat the 
signal transduction mechanism triggered by IFN-7 may 
involve a role for a GTP.binding protein [6] and/or that 
of protein tyrosine/serine kinases [7], including protein 
kinase C [8] and Ca-~+/calmodulin-dependent kinase 
pathways [9]. However, the intracellular mechanism(s) 
that mediate lFN-?,-induced responses have yet to be 
fully elucidated, particularly as it relates to the induc- 
tion of cell differentiation. Increasing evidence supports 
a role for arachidonic acid (AA) metabolites in the con- 
trol of neuronal cell differentiation and, although IFN- 
2" initiates its action through binding to a specific recep- 
tor distinct from that recognizing IFN-~/fl [10], very 
recently it has been shown that IFN-~ induced the tran- 
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sient activation of phospholipase A.~ (PLA,.) in 3T3 fi- 
broblasts [11]. Since stimulation of PLA., is a common 
source of second messengers for receptor-mediated sig- 
naling [12,13], we tested whether activation of PLA~ 
followed IFN-~" stimulation of human neuroblastoma 
cells. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
All lipid standards and inhibitors were purchased from Sigma (St. 
Louis, Me, USA). Human recombinant IFN-?. was obtained from 
Genzyme Corp. (Boston, MA, USA). IFN-?. (I,000 U/#I) wan kept in 
aliquots in phosphate.buffered saline (PBS) (Flow Laboratori~, 
Milan, Italy) plus 0.1% bovine ~rmn albumin (BSA) at -80"C. 
2.2. Cell cnltures 
The LAN-5 NB cell line was a gift from R. Seeger [14]. C~ils were 
maintained in the logarithmic phase of growth in 75-cm ~ plastic ul- 
ture flasks (Falcon Plastic, Oxnard, CA, USA) in RPMI 1640 medium 
(Flow) supplemented with 10% heat-inactivated f tal ealfseaum (FCS) 
(Seromed, Biochrom KG, Berlin, Germany), "sodium l~nieillin G (50 
IU/ml), and streptomycin sulfate (50 prdml) (complete medium) at 
37"C in a 5% CO:-95% air humidified incubator. Cells were split 
following treatment with 1 mM EDTA in Hunk's salts solution 
(Flow), washed, counted, and re.plated in fresh complete medium. 
2.3. Release of celhdar [~HJAA in LAN-5 cells 
LAN-5 cells (5 x 10S/wall in 24.well plates) were la!~led for 24 h at 
37"C with [~H]AA (0. I mCi/ml, Amersham) in RPM! 1640 complete 
m,z'dium. Alter lal~ling, monolayer ~lls were washed three times with 
complet~ medium at 37"C. For time-course experiments, RPMI 1640 
with IFN-?. (1,000 U/ml) was added at time zero after washing. At the 
different time points examined, aliquots from quadruplicate w lls tbr 
each time were measured for [~HIAA rel~nt.~.,d into the culture medium 
using aft scintillation counter. [~HIAA release was dose-dependent a d 
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maximal between 800 and 1,000 U oi" IFN-7 per ml. in order to 
confirm uptake of label into appropriate pools, [~H]AA-labeled 
phospholipids were analyzed by thin layer chromatosraphy [15]. Typ- 
ically, about 35-40% of added [aH]AA was incorporated into lipids. 
Under these condition, the lipid profile of incorporated [~H]AA was 
phosphafidylcholine (PC) (53 + 2%), lysopC (10 __. 2%), phosphat- 
idylethanolamine (PE) (10 -+ 3%), lysoPE (9 + 3%), phosphatidyl- 
inositol (PI) (11 +_. 2%), and phosphatidyl- serine (PS) (8 -+ 2%7. For 
the inhibition experiments, after washing, labeled LAN-5 cells were 
pretreated for 10 min at 37°C with bromophenaeyl bromide (BPB) (10 
#M), and then treated with or without i,000 U/ml IFN-?, or pre- 
treated for 10 rain at 37°C with indomethacin (INDO) (10 #M) or 
nordihydrogaaiaretic acid (N DGA) (10 ~tM)and then treated with or 
without 200 U/ml IFN- 7, After 2 min and 30 s at 37°C aliquots were 
counted ror ['*H]AA release as above. 
2.4. Production oJ" l),soPC hi LA N.5 N8 cell line 
LAN-5 cells (1 x 10" cells/25-cm" flask) were labeled overnight at 
37°C with 20 #Ci/ml of carrier-free [~:P]orthophosphate (Amersham, 
10 mCi/ml) in phosphate-free RPMi 1640 supplemented with 10% 
dialyzed FCS. After labeling, monolayers were washed three times 
with RPMI 1640 at 37°C, and treated at 37°C for different times with 
or without IFN- 7 (1°000 U/ml). At indicated time points the medium 
was aspirated and cells harvested by scraping in ice-cold PBS. and 
labeled lipids extracted [16]. Chromatographic separation ofthe major 
phospholipid subclasses was carried out on Silica Gel LK5 TLC plates 
(Whatman) [17]. For the separation of lysophospholipids, LK6 TLC 
plates were developed as described [i5]. LysoPS and lysoPl were run 
together in this system. The a"P-labeled phospholipids were visualized 
by autoradiography and identified by co-chromatography with unla. 
beled standards detected by iodine vapour. To test he effects of 1NDO 
and NDGA on the production of lysoPC, LAN-5 cells were labeled 
as described above. After washing, cells were pretreated for 10 rain at 
37°C with BPB (10,aM) and then stimulated or not with 1,090 U/ml 
IFN- 7, or pretreated with INDO (10#M) or NDGA (10yM) and then 
stimulated or not with 200 U/ml IFN-~,. After 5 rain at 37°C the cells 
were extracted for lipids analysis and processed as above. 
3. RESULTS AND DISCUSSION 
It has been previously shown that IFN-  7 is able to 
promote concentration-dependent growth inhibition of  
a neuroblastoma cell line, LAN-5, together with striking 
morphological  changes and modulation of membrane 
and cytoskelctal proteins [18]. IFN-~'-induced LAN-5 
cells rapidly acquired a pattern similar to that observed 
in mature ganglioneurocytes [18]. This cell line ex- 
presses high levels of  the high-affinity IFN-7 receptor 
(Ka = 4.53 +_. 0.19 x 10 -m, Bm,,.~ " 7,164 __. 377 sites) in 
agreement with data in other unrelated models [5]. 
A consequence of membrane PLA: activation is the 
release of AA from membrane phospholipids, typically 
from phosphatidylcholine (PC) or phosphatidylinositol 
(PI) [12]. Arachidonic acid can then be metabolized to 
prostaglandins, thromboxanes, and leukotrienes via cy- 
clooxygenase- or lipoxygenase-catalyzed r actions, re- 
spectively [19]. Treatment of [~H]AA-labeled LAN-5 
cells with a receptor-saturating concentration of  I FN-y  
(1,000 U/ml) led to a rapid and time-dependent release 
t' za j , .~ into the culture media "~:- "" t  ~s. I~1 .  Pretreat- 
merit o f  cultures with the PLA:  inhibitor, bromophena-  
cyl bromide (BPB, 10 #M)  markedly inhibited both 
basal and stimulated [~H]AA release (Fig. I B), clearly 
200 
I H 
=t " "  ~0 
0 
i i 
10 
IFN-~ 
) , / .¢ ,  j 
20 30 50  60  
t reatment  (rnin) 
A 
300 
"~ 250 
< . 1~0 
50 
B 
T 
i 
Fig. 1. Stimulation of release of cellular [3H]AA by IFN-), in LAN-5 
cells. (A) Time.dependent release of [31-1]AA by IFN-~, treatment. (B) 
Effects of inhibitors of PLA:. cyeloaxygenase, and lipoxygenase en- 
zymes (BPB, INDO, and NDGA, respectively) on the release of 
[.~I-I]AA induced by treatment with IFN-7 for 2.5 min. The results in 
A are representative of five independent experiments, and those in B 
represent three independent experiments each done in duplicate ('P< 
0.05; "'P<0.001, evaluated by Student's t-test for unpaired ata). 
indicating a constitutive activation of PLA2 in our 
model as well as an increase in AA metabolism in re- 
sponse to IFN-~,. The possibility of  an AA release by 
phospholipase C activation and subsequent deacylation 
of diacylglyceroi in response to IFN-7  has been previ- 
ously ruled out [20]. 
Further evidence of PLA2 activation in response to 
IFN.-?" was obtained by measuring [3H]AA release in 
LAN-5 cells treated with subsaturating amounts of 
IFN-?" (200 U/ml) after pretreatment with NDGA (10 
MM), a lipoxygenase inhibitor, or INDO (10 MM), a 
cyclooxygenase inhibitor. Both inhibitors led to a 
marked amplification of  the release of  [aH]AA induced 
. . . . . .  :.. ,= t ,  , . . . .  m ....  (Fig. lm ,r,,a,,.~,~,, by , lon-sa,,t,, , , , ,g ,, N-7 . . . .  ~ ~,  . - ,  ~- . . . . . . . .  ,, 
a relative amount of  [3H]AA released identical to that 
induced by saturating concentrations of 1FN-~'. Pre- 
treatment of LAN-5 cells with 50 #M BW577C, an 
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Fig. 2. (A) Chromatosraphie separation of the major phospholipid sube, hlsses. (B) Separation of iysophospholipids. The TLC plates were exposed 
to Kodak X-AR-5 films for I day (A and B, magnification xl) or for 3 days (B insets, magnification ×1,5). Lane 1, untreated cells; lanes 2-5, cells 
treated with IFN.y for 2.5, 5, 15 and 60 min. respectively. Quantification ol'3'P incorporated into phospholipids was determined by scraping the 
labeled phospholipids off the plates and liquid scintillation counting (C and D). Radioactivity applied at the orisin of the TLC plates (I 5,000 epm 
per track, A and B; 30,000 cpm per track, insets) was used as a me, asur¢ of total -~:P-labeled phospholipids. Results are the average +- S.D. of thr¢¢ 
independent experiments each done in duplicate ('P <0.05; "'P <0.001 evaluated by Student's t-test for unpaired ata). The percentage of
unstimulated levels were: 45 :I: 4,5, PC; 22 _ 2.5, PE; 13 + i.5, PI; 10 + 2, PS; 4.5 _+ 0.75, PA; 3 - 0.25, lysoPC; I.I __. 0.3. PIP; 0.6 _+ 0.2, PIP2; 
0.5 +_ 0.15, lysoPE; 0.3 _ 0.1, lysoPS + lysoPI. The positions of phospholipid standards are marked on the margins: PC, phosphatid2cleholin¢; PE. 
phosphatidylethanolamin¢; PS, phosphatidylserin¢; PA, phosphatidic a id; PI, phosphatidylinositol; PIP, phosphatidylinositol 4 .phosphate; PIP,. 
phosphatidylinositol 4.5-bisphosphat¢; lysoPE, lysopho~phatidylethanolamine; lysoPS, lysophosphatidylserine; lysoPl, lysophosphutid~'linositol; 
lysoPC, lysophosphatidyleholine. 
inhibitor of both lipoxygenas¢ and eyclooxygenase en- 
zymes, also resulted in amplification of the signal gener- 
ated by non-saturating IFN-7 treatment (data not 
shown), It is noteworthy that a significant increase in 
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Fig, 3, Effects of inhibitor~ of PLA,, eydooxygcnase, and lipoxyge- 
na6¢ enzyme.~ (BPB, INDO, and NDGA, respectively) on the produc- 
tion of lysoPC (A) and hydrolysis of PC (B). The data are mean~ + 
S.D. of three independent experiments each done in duplicate 
('P< 0.05; "'P<0.001, evaluated by Student's t.test). 
the release of [3H]AA was observed in untreated cul- 
tures by INDO alone, indicating a possible negative 
feedback exerted by some prostanoids in basal condi- 
tions. 
The other product of PLA_~ action is a lysophospho- 
lipid. To further prove PLA: activation LAN-5 cells 
were labeled overnight with [~-~P]orthophosphate and
treated with IFN-7 for various times. Labeled extracts 
were then analyzed by thin layer chromatography for
IFN-7-stimulated production of lysophospholipids and 
degradation ofprecursor phospholipids (Fig. 2). Within 
2 min of IFN-7 treatment, lysoPC was increased by 
30%, with a maximum increase of 70% after 5 min, 
relative to the amount from unstimulated cells. By 60 
mix after IFN-7 treatment, lysoPC returned to near 
basal evels (Fig. 2B,C). In parallel, with the same time- 
i . -¢~l~, - .nn*  ,4 . . . .  . a~a h ' .  PC  I~ l ' ,a l ;~ ,v  
was observed in IFN-treated cells (Fig. 2B,D), indicat- 
ing a hydrolysis of PLA2 of membrane PC as the signal 
transduction mechanism of IFN-7. Lysophosphatidyl- 
ethanolamine (lysoPE) and lysophosphatidylinositoi 
were not elevated in extracts of IFN-7-treated cells (Fig. 
2B insets), and, accordingly, no differences were ob- 
served in PE and PI labeling between treated and un- 
treated cultures (Fig. 2A). 
The transient nature of the PLA.~ response iscompat- 
ible with its potential participation i signaling by IFN- 
7. The lasting activation of PLA.,, still observed after 15 
mix (Figs. 1 and 2), could be accounted for by a conse- 
quent platelet activating factor activation of PLA~ by 
release of intracellular Ca :+ stores [21]). 
In agreement with what was shown for [~H]AA re- 
lease, pretreatment of LAN-5 cells with BPB blocked 
both basal and IFN-7-induced hydrolysis of PC with 
consequent inhibition of the production of lysoPC (Fig. 
3A,B). Significantly, pretreatment of control cells with 
INDO gave a slight but reproducible PLA: stimulation 
(Fig. 3), confirming the hypothesis that, in neuroblas- 
toma cells, some prostanoids may play a role as nega- 
tive regulators of PLA2 activation, or simply amplify 
constitutive PLA: activation. It is noteworthy that 
INDO pretreatment was also able to enhance PC hy- 
drolysis induced by non-saturating concentrations of
IFN-~', indicating that, besides the expected accumula- 
tion of the hydrolysis products, a prostanoid(s) might 
also exist in the IFN-7-stimulated PLA.~ activation 
working as a negative PLA~ regulator. The higher in- 
crease of INDO-sustained AA release in IFN-7-treated 
cells, with respect o untreated cultures, suggests that 
this control may be exerted at the level of receptor de- 
sensitization. Thus, inhibition of PLA.~ and of AA me- 
tabolism through cyclooxygenase and lipoxygenase ys- 
tems affects early signals generated by IFN-7 binding 
to its receptor in the neuroblastoma odel. This conclu- 
sion is supported by experiments in which the treatment 
of LAN-5 cells with 500 U/ml of IFN-7 induced the 
expression of 2',5'-oligoadenylate synthetase [22], and 
this induction was completely abolished by pretreat- 
ment with BPB (data not shown). However, the forma- 
tion of the putative regulatory AA metabolite could not 
occur via cyclooxygenase or lipoxygenase pathways. 
Thus, substrate AA derived from IFN- 7 receptor acti- 
vation might be redirected from cyclooxygenase- and 
lipoxygenase-catalyzed transformation to another AA 
metabolic pathway (i.e. epoxygenase-catalyzed AA con- 
versions would not be inhibited by INDO and NDGA) 
p3]. 
In conclusion, our results uggest that stimulation of 
receptor-coupled PLA: and AA metabolism ay partic- 
ipate in signaling IFN-7-generated responses. Since 
prostanoids, particularly prostaglandins, are able to in- 
duce differentiation of neuroblastoma, both in vitro 
[24,25] and in vivo [26], an intriguing question is 
induction of neuroblastoma cell maturation by IFN-7. 
To this purpose we are investigating whether pretreat- 
ment of LAN-5 cells with INDO or NDGA can prevent 
20 
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the maturat ive ffects o f  IFN-7 .  Moreover ,  the possibil- 
ity that the addit ion o f  specific AA-der ived autocoids 
can revert the blockade induced by INDO and/or  
NDGA is currently being probed. 
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